First Manhattan’s Myovant Sciences Ltd. MYOV Stock Holding History

First Manhattan’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-400,000	Closed	-$3.62M	–	1428
2019 Q2	$3.62M	Buy	400,000 +382,195	+2,147%	+$5.7M	0.02%	268
2019 Q1	$425K	Hold	17,805	–	–	﹤0.01%	583
2018 Q4	$292K	Buy	+17,805	New	+$351K	﹤0.01%	622

Other funds holding MYOV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Manhattan's MYOV Position: Q3 2019 in Review

First Manhattan sold out of Myovant Sciences Ltd. (MYOV) in Q3 2019, closing a stake of 400,000 shares — an estimated $3.62M sold.

First Manhattan first reported a position in MYOV in Q4 2018 and held it in 3 quarters. The position peaked at $3.62M in Q2 2019. 65 funds tracked by Wall St. Rank hold MYOV as of Q3 2019.

First Manhattan reported no remaining Myovant Sciences Ltd. position as of Q3 2019 after selling out during the quarter.
First Manhattan sold 400,000 Myovant Sciences Ltd. shares in Q3 2019, an estimated $3.62M.
First Manhattan first reported a position in Myovant Sciences Ltd. in Q4 2018 and held it in 3 quarters.
First Manhattan's Myovant Sciences Ltd. position peaked at $3.62M in Q2 2019.
65 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q3 2019.

Based on First Manhattan's 13F filing for Q3 2019, filed 13 Nov 2019.